-
Study aim
-
Determination of the effect of synbiotic supplementation on glycemic indices, inflammatory biomarkers (hs-CRP, TNFα) and appetite in patients with metabolic syndrome
-
Design
-
A randomized, placebo-controlled, double-blind parallel-group clinical trial. Fourty eight participants will be randomly allocated to two groups, one group receives synbiotic (n = 24) and another group receives placebo (n = 24).
-
Settings and conduct
-
individuals with metabolic syndrome will be recruited from Isfahan Endocrine & Metabolism Research Center (IEMRC), Isfahan, Iran.The synbiotic supplements and placebos will be packed in similar boxes, and the researcher and the patients will not be aware of the content of the pack until the end of the study.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: willingness to participate ;
age of 20 to 55 years
BMI > 25 kg/m2
waist circumference ≥88 cm in women and waist circumference ≥102 cm in men, serum triglyceride ≥150 mg/dl , serum HDL cholesterol <40 mg/dl in men and <50 mg/dl in women, fasting blood glucose ≥100 mg/dl
Exclusion critaria :participating in weight loss or weight gain programs ; history of mental disease,cancer,cardiovascular disease.
Thyroid, pulmonary,renal and hepatic problems,eating disorders Pregnant,lactating and post menopausal women;
Taking any dietary supplements,probiotic , prebiotic and synbiotic food products, antibiotics, drugs that affect appetite and body weight, and anti-inflammatory drugs ;
History of allergies to probiotics , prebiotics and maltodextrin products
-
Intervention groups
-
Individuals will be divided into two groups to receive two 500 mg synbiotic capsules or two 500 mg placebo capsules per day for 8 weeks.
-
Main outcome variables
-
Fasting blood sugar, fasting insulin,HOMA-IR, quantitative insulin sensitivity check index, High Sensitivity C-Reactive Protein, Tumor necrosis factor-α and appetite